Results of comparison of the effectiveness of adalimumab and ixekizumab in the treatment of psoriasis
- Authors: Sarsur S.K.1, Rudneva N.S.2,3
-
Affiliations:
- Kabardino-Balkarian State University n.a. Kh.M. Berbekov
- Tula Regional Clinical Dermatovenerological Dispensary
- Medical Institute of Tula State University
- Issue: Vol 30, No 13 (2023)
- Pages: 42-46
- Section: Original articles
- URL: https://ogarev-online.ru/2073-4034/article/view/275636
- DOI: https://doi.org/10.18565/pharmateca.2023.13.42-46
- ID: 275636
Cite item
Open Access
Access granted
Subscription Access
Abstract
Background. Psoriasis (PS) is a chronic non-infectious disease of an autoimmune nature, which is characterized by predominantly skin lesions.
Objective. Determination of the clinical effectiveness of adalimumab and ixekizumab in the treatment of PS.
Methods. The study involved 140 patients, 87 (62.14%) men and 53 (37.86%) women aged 18–60 years (mean age 38.2±11.7 years). The effectiveness of therapy was assessed after 4, 8, 12, 52 weeks and 2 years. The severity of PS was assessed using the PASI, BSA, sPGA indices. The quality of life of the study participants was assessed using the Dermatological Quality of Life Index (DIQL) and the HADS Hospital Anxiety and Depression Scale.
Results. All 140 patients completed the study. At week 12 of therapy, complete clinical remission was achieved in 40% of patients receiving ixekizumab. In the group of patients receiving adalimumab, complete remission was achieved in 7%.
Conclusion. Ixekizumab showed higher efficacy rates in the treatment of vulgar PS than adalimumab, and therefore can be recommended for the treatment of vulgar PS.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Sh. Kh.R. Sarsur
Kabardino-Balkarian State University n.a. Kh.M. Berbekov
Author for correspondence.
Email: Dr.shadi.sarsour@gmail.com
ORCID iD: 0000-0002-9565-5469
Postgraduate Student, Department of Infectious Diseases, Faculty of Medicine
Russian Federation, NalchikN. S. Rudneva
Tula Regional Clinical Dermatovenerological Dispensary; Medical Institute of Tula State University
Email: pharmateca@yandex.ru
ORCID iD: 0000-0002-0621-5518
Russian Federation, Tula; Tula
References
- Parisi R., Iskandar I.Y.K., Kontopantelis E., et al. Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590.
- Gran F., Kerstan A., Serfling E., et al. Current Developments in the Immunology of Psoriasis. Yale J Biol Med. 2020;93(1):97–110.
- Raharja A., Mahil S.K., Barker J.N. et al. Psoriasis: a brief overview. Clin. Med. (Lond). 2021;21(3):170–73. doi: 10.7861/clinmed.2021-0257.
- Hawkes J.E., Chan T.C., Krueger J.G. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–53.
- Singh R., Koppu S., Perche P.O., et al. The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. Int J Mol Sci. 2021;22(23):12793. doi: 10.3390/ijms222312793.
- Gianfredi V., Casu G., Bricchi L., et al. Epidemiology of psoriasis in Italy: burden, cost, comorbidities and patients’ satisfaction. Acta Biomed. 2022;93(6):e2022332. doi: 10.23750/abm.v93i6.13177.
- Loft N., Skov L., Richardson C., et al. A nationwide population-based cohort study of the incidence of severe and rare infections among adults with psoriasis in Denmark. Br J Dermatol. 2022;187(3):353–63. doi: 10.1111/bjd.21595.
- Grodner C., Sbidian E., Weill A., et al. Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database. J Eur Acad Dermatol Venereol. 2021;35(2):411–16. doi: 10.1111/jdv.16566.
- Кунгуров Н.В., Кениксфест Ю.В., Гришаева Е.В., Кохан М.М. Клинический опыт применения препарата иксекизумаб в терапии пациентки с тяжелым псориазом и псориатическим артритом, резистентными к терапии. Лечащий врач. 2020;5:42. [Kungurov N.V., Keniksfest Yu.V., Grishaeva E.V., Koxan M.M. Clinical experience with the use of ixekizumab in the treatment of a patient with severe psoriasis and psoriatic arthritis resistant to therapy. Lech Vrach. 2020;5:42.].
- Коротаева Т.В. Результаты прямого сравнения клинической эффективности иксекизумаба и адалимумаба: данные исследования SPIRIT H2H. Современная ревматология. 2020;14(3):50–6. [Korotaeva T.V. Results of a direct comparison of the clinical efficacy of ixekizumab and adalimumab: data from the SPIRIT H2H trial. Sovrem Revmatol. 2020;14(3):50–6.].
- Reich K., Kristensen L.E., Smith S.D., et al. Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naive Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial. Dermatol Pract Concept. 2022;12(2):e2022104. doi: 10.5826/dpc.1202a104.
Supplementary files
